Around 30% of people aged 65 and above have diabetes in the United States, according to the American Diabetes Association. Diabetes patients experience a greater risk of developing dementia as compared to people without diabetes. A study has shown that Type 1 diabetics are 93% more likely to be affected by dementia. Thus, the rising burden of diabetes and its association with dementia is augmenting the need for treatments that can address both conditions. This growing demand is likely to lead to significant investments in expanding the drug pipeline and manufacturing capacities.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to dementia with diabetes.
For the management of diabetes in individuals with dementia, some diabetes drugs can help slow the progression of dementia and enhance cognitive function. In some studies, metformin is reported to decrease the risk of memory and thinking problems. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, used primarily for type 2 diabetes, may also reduce the risk of dementia. With substantial investments by pharmaceutical companies, adherence to dementia with diabetes treatment guidelines, and the growing focus on targeted therapies, the drug pipeline is expected to expand in the coming years.
According to a study published in Diabetes Care (2024), people diagnosed with diabetes in middle age have a higher lifetime risk of dementia (36%) compared to those diagnosed later in life (31%). By age 80, the dementia incidence is also higher in middle age-onset diabetes cases (16.1%) compared to those without diabetes (9.4%). Moreover, dementia tends to appear 4 years earlier for people with middle age-onset diabetes compared to those without diabetes.
Biological: PrimePro™/ PrimeMSK™
This Phase II clinical study is aimed at examining the efficacy, tolerability, and safety of stem cell therapy PrimePro™/ PrimeMSK™ for various chronic and acute conditions including diabetes complications and neurologic or neurodegenerative disorders. The interventional study has enrolled about 5000 subjects and is expected to be completed by December 2030.
This product will be delivered within 3-5 business days.
Report Coverage
The Dementia with Diabetes Drug Pipeline Insight Report by the publisher gives comprehensive insights into dementia with diabetes drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for dementia with diabetes. The dementia with diabetes report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The dementia with diabetes pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with dementia with diabetes treatment guidelines to ensure optimal care practices.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to dementia with diabetes.
Dementia with Diabetes Drug Pipeline Outlook
Diabetes is considered a major risk factor for dementia, which is stimulating the development of novel dementia with diabetes therapeutics. It is reported that type 2 diabetes patients are prone to developing dementia, particularly vascular dementia. Studies have shown that low blood sugar level or hypoglycemia is linked to brain cell degeneration and cognitive decline whereas high blood sugar levels are associated with Alzheimer's disease.For the management of diabetes in individuals with dementia, some diabetes drugs can help slow the progression of dementia and enhance cognitive function. In some studies, metformin is reported to decrease the risk of memory and thinking problems. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, used primarily for type 2 diabetes, may also reduce the risk of dementia. With substantial investments by pharmaceutical companies, adherence to dementia with diabetes treatment guidelines, and the growing focus on targeted therapies, the drug pipeline is expected to expand in the coming years.
Dementia with Diabetes Epidemiology
Recent epidemiological studies have suggested the increasing prevalence and incidence of dementia in diabetes patients. Several meta-analyses have estimated that diabetes increases the risk of dementia by nearly half among the patient population.According to a study published in Diabetes Care (2024), people diagnosed with diabetes in middle age have a higher lifetime risk of dementia (36%) compared to those diagnosed later in life (31%). By age 80, the dementia incidence is also higher in middle age-onset diabetes cases (16.1%) compared to those without diabetes (9.4%). Moreover, dementia tends to appear 4 years earlier for people with middle age-onset diabetes compared to those without diabetes.
Dementia with Diabetes - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of dementia with diabetes drugs based on several segmentations including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Proteins and Peptides
- Small Molecules
- Hormones
- Enzymes
By Route of Administration
- Oral
- Parenteral
- Others
Dementia with Diabetes - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials, with a substantial number of dementia with diabetes emerging drugs.Dementia with Diabetes - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under dementia with diabetes pipeline analysis include proteins and peptides, small molecules, hormones, and enzymes. The dementia with diabetes report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for dementia with diabetes.Dementia with Diabetes Clinical Trials Therapeutic Assessment - Competitive Dynamics
The report for dementia with diabetes drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed dementia with diabetes therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in dementia with diabetes clinical trials:- HiDO Technologies
- Bespoke Clinical Research
- MD Stem Cells
- Thomas Advanced Medical LLC
- Sanguine Biosciences
Dementia with Diabetes - Emerging Drugs Profile
Major drugs currently in the drug pipeline are as follows:
Drug: Ginkgo Ketone Ester Tablets
The objective of this multicenter randomized double-blind controlled clinical study is to evaluate the efficacy and safety of dementia with diabetes drug candidate Ginkgo biloba ketone ester tablets, containing extracts of Ginkgo biloba leaves, for the treatment of diabetes related dementia in type 2 diabetes patients with mild cognitive impairment. The study is under Phase IV clinical development and has an estimated 370 participants.Biological: PrimePro™/ PrimeMSK™
This Phase II clinical study is aimed at examining the efficacy, tolerability, and safety of stem cell therapy PrimePro™/ PrimeMSK™ for various chronic and acute conditions including diabetes complications and neurologic or neurodegenerative disorders. The interventional study has enrolled about 5000 subjects and is expected to be completed by December 2030.
Reasons To Buy This Report
The Dementia with Diabetes Drug Report provides a strategic overview of the latest and future landscape of treatments for dementia with diabetes. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within dementia with diabetes pipeline insights.Key Questions Answered in the Dementia with Diabetes - Pipeline Insight Report
- What is the current landscape of dementia with diabetes pipeline drugs?
- Which companies/institutions are developing dementia with diabetes drugs?
- How many phase III and phase IV drugs are currently present in dementia with diabetes pipeline drugs?
- What is the efficacy and safety profile of dementia with diabetes drug candidates?
- What are the opportunities and challenges present in the dementia with diabetes drug pipeline landscape?
- What geographies are covered for dementia with diabetes clinical trials?
- What are emerging therapies in dementia with diabetes clinical trials?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Dementia with Diabetes
4 Patient Profile: Dementia with Diabetes
5 Dementia with Diabetes: Epidemiology Snapshot
6 Dementia with Diabetes: Market Dynamics
7 Dementia with Diabetes: Key Facts Covered
8 Dementia with Diabetes, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Dementia with Diabetes Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Dementia with Diabetes Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Dementia with Diabetes Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Dementia with Diabetes Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Dementia with Diabetes, Key Drug Pipeline Companies
